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Radioiodine diagnosis of disseminated recurrent thyroid can-
cer and radioiodine treatment are in most cases unachievable
without stimulation of cancer cells by thyrotropin (TSH) (1, 2, 3).
TSH stimulation is needed for nearly all functions of the thyroid
cell, particularly for its hormonal activity, but also for its prolifera-
tion (3, 4, 5). The thyroid-specific functions are dependent on the
expression of thyroid-specific genes, such as sodium iodide sym-
porter, thyroperoxidase, thyroglobulin or the TSH receptor gene
(6). The expression of these genes is reduced in differentiated
thyroid cancer (DTC) to a variable extent, and this results in an
impairment of the functions of cancer cells (6, 7). The effect may
be detected already on the clinical level, because iodine trapping
by cancer cells is much less efficient in comparison to normal
follicular cells. Thus, preoperatively, a malignant tumour of the thy-
roid is seen mostly as a cold lesion on the scintigram. Post sur-
gery, when the thyroid gland is removed and the remnants are
destroyed by 131I ablation, the 131I uptake becomes visible, which
enables the early detection of cancer spread and indicates 131I
therapy (8).
Stimulation with TSH is able to increase iodine uptake and
organification in thyroid cancer cells (Figure 1) (5, 9, 10, 11). This
is important for the visualisation of cancer foci on a radioiodine
scan, and is also essential for the improvement of the sensitivity
of thyroglobulin testing (12, 13, 14). The rise in endogenous TSH,
achieved by a 46 week thyroxine withdrawal, is most often used
to reach this goal. However, this is connected with symptomatic
hypothyroidism (Table 1) (9, 14, 15). The introduction of recombi-
nant human TSH (rhTSH) (16, 17, 18, 19) has created a chance to
perform both therapy and follow-up without pauses in thyroxine
administration (3, 20). The diagnostic use of rhTSH in thyroid can-
cer patients has already been approved on the basis of extensive
multi-centre studies carried out in the last few years (9, 10, 21).
The second phase III clinical study showed that results of endo-
and exogenous TSH stimulation were quite comparable on iodine
scans (10). Circa 89% of scans performed while on rhTSH gave
identical results as compared to the routine thyroxine withdrawal
procedure. Even when only positive scans were compared, about
75% were concordant, and in some cases, recombinant TSH was
more effective.
Figure 1. TSH impact on radioiodine uptake.
Table 1. Incidence of hypothyroidism symptom during thyroxine
withdrawal (modified according to Billewicz)
Frequency range Symptoms
> 50% Periorbital swelling
Slow movements
Cold intolerance
Weight increase
2050% Slowing of the ankle jerk reflex
Decrease in heart rate
Constipation
Hoarseness
Dry skin
< 20% Diminished sweating
Paraesthesia
Rough skin
Deafness
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The accepted procedure consisted of repeated intramuscular
injections of 0.9 mg rhTSH for two consecutive days and 131I ad-
ministration on day 3, with whole body scans (WBS) performed
48h after radioiodine administration (Figure 2). Due to the lower
iodine renal clearance during thyroxine withdrawal-induced hy-
pothyroidism, the activity of 131I given was doubled from 2 to 4
mCi during rhTSH aided diagnostics.
According to the published results of multi-centre studies (9,
10, 21) only minor and negligible side effects were observed dur-
ing diagnostic rhTSH use. Their rare occurrence was in striking
contrast to the frequent symptoms of hypothyroidism, seen after
thyroxine withdrawal in the same patients (14, 15) (Table 1). Al-
though those symptoms do not belong to the life-threatening cat-
egory and do regress after reintroduction of thyroxine, the quality
of life is lowered significantly during the hypothyroid phase. The
major loss was seen in physical and emotional roles as estimated
on the basis of psychological tests (15, 22).
When we compare the serum TSH rises induced by rhTSH
and thyroxine withdrawal, the first is more distinct but shorter  the
two im injections result in a 56 day long increase (Figure 3). Al-
though rhTSH is able to stimulate the 131I uptake very efficiently,
circa 815% of scans performed under rhTSH yield poorer results
in comparison to thyroxine withdrawal (9, 10). This problem may
be solved by a concomitant estimation of the thyroglobulin (Tg)
serum level (10). When a Tg rise is observed after rhTSH stimula-
tion but the 131I WBS is negative, a repeated diagnostic after thy-
roxine withdrawal should be performed in order not to miss dis-
tant metastases. In the second phase III study the joined analysis
of rhTSH-stimulated 131I whole body scans and thyroglobulin se-
rum levels yielded 100% sensitivity in the detection of hidden can-
cer foci and 93% sensitivity in patients with disease or tissue lim-
ited to the thyroid bed (10). However, the specificity of the rhTSH-
stimulated Tg estimation has not yet been determined. It is obvi-
ous that different cut-off levels should be applied for Tg estima-
tions under rhTSH, as this stimulation results in a weaker Tg re-
sponse than thyroxine withdrawal (10, 23, 24).
The therapeutic use of recombinant human TSH has not yet
been approved and intensive multi-centre studies are currently
being conducted. In this paper we would like to analyse the re-
ports published until now (2527) and our own experience with
rhTSH used during therapy of disseminated thyroid carcinoma
(23, 24), mainly in the context of the priority of indications for rh-
TSH aided treatment.
The therapeutic use of radioiodine in cancer disease implies
that after radioiodine administration a sufficient quantity of radio-
isotope will be concentrated providing the tumoricidal dose of beta
radiation energy (28, 29). Thus, TSH is needed not only for stimu-
lation of iodine trapping but also for its longer retention by thyroid
cancer cells. The clinical advantages of the use of recombinant
hTSH in the radioiodine therapy are quite clear, as the risk of hy-
pothyroidism may be omitted (9, 10, 20). However, it is necessary
to document that the transient stimulation with exogenous TSH is
sufficient to accumulate 131I long enough to obtain the regression
of cancer disease and the complete ablation of thyroid remnants.
Only when this is proved, will rhTSH aided 131I therapy be indicat-
ed for all DTC patients. The realisation of this ideal goal will prob-
ably take a long time, because of both logistic and financial rea-
sons. So, we have to analyse and evaluate the most important,
unquestionable indications for recombinant TSH application.
The main indications for rhTSH aided iodine therapy are sum-
marised in Table 2. It is clear that recombinant TSH is to be ap-
plied in patients, in whom it is impossible to achieve stimulation
with endogenous hormone. Obviously, pituitary insufficiency with
secondary hypothyroidism in a patient with differentiated thyroid
cancer requiring 131I therapy is a classical indication for recombi-
nant human TSH administration (3032). However, these are both
rare diseases and only a few patients suffer simultaneously from
each of them. The published casuistic results clearly show that
the use of recombinant TSH increases the target to background
ratio very well in these cases. Most of them concern patients with
DTC metastases destroying the pituitary gland (26, 32, 33).
The most frequent clinical situation, where endogenous TSH
is low and may not be increased by thyroxine withdrawal, is an
inoperable cancer disease, where the production of endogenous
thyroid hormones is high enough to prevent TSH rise. Mostly, these
hormones are produced by the surrounding normal follicular cells.
When the operation is not possible, we have first to destroy nor-
mal thyroid tissue by radioiodine and only then further treatment
of cancer disease by the next 131I therapy is to be considered (34).
This is a time-consuming process and during the period required
to destroy thyroid tissue cancer progression may proceed. The
use of recombinant TSH at the first therapeutic 131I iodine adminis-
tration would be beneficial through the activation of radioiodine
uptake in the tumour, which presents at this time as a cold lesion.
We considered the possibility of rhTSH administration in a patient
who presented with a metastatic brain tumour, concentrating 131I,
as the first symptom of DTC. However, our application has been
Figure 2. rhTSH administration schedule before 131I therapy.
Figure 3. Serum TSH after exogenous rhTSH application.
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rejected, due to the risk of the induction of thyroid storm. It has
been shown by Ramirez and Braverman et al. (35) that recombi-
nant TSH stimulates normal thyroid very efficiently. RhTSH amounts
of 0.1 mg (i.e. much lower than those applied in DTC athyroid
patients) are able to stimulate thyroid hormone secretion in healthy
subjects up to the levels seen in hyperthyroidism. So, the clinical
consequences of the induced hyperthyroidism in patients with the
preserved thyroid gland must be considered. Further clinical stud-
ies are urgently needed to solve the question, whether the risk of
thyroid storm in patients with preserved thyroid is substantial. In
our opinion the administration of rhTSH could be a very promising
help for 131I therapy in inoperable primary thyroid cancer.
Recombinant TSH is also considered when functional DTC
metastases are the source of excessive thyroid hormones, which
lower the endogenous TSH level. The opponents indicate that
hormonally active metastases will also concentrate iodine, so the
help from recombinant TSH may not be so important. One very
interesting case report has been published recently (27), where
recombinant human TSH was applied to stimulate iodine uptake
in the liver metastases of a malignant struma ovarii with overt hy-
perthyroidism due to their hyperfunction. A careful dosimetric anal-
ysis was performed after diagnostic iodine application under rhT-
SH stimulation. The single course of 131I therapy under rhTSH re-
sulted in a very distinct regression of liver metastases. A 78% up-
take of administered iodine in liver metastases was obtained. The
authors did not perform a basic study of 131I uptake, so it is not
known to what extent the very high uptake of iodine in metastases
was due to the administered recombinant TSH (the basal uptake
may not be neglected, as liver metastases were able to induce
hyperthyroidism in this patient). However, the results indicate the
possibility of a significant increase in the efficacy of 131I therapy by
recombinant TSH. Interestingly enough, no aggravation of hyper-
thyroidism was observed under metoprolol pretreatment, although
the rise of T3 up to 310 ng/ml was stated.
Another group of indications for rhTSH encompasses the
known contraindications to thyroxine withdrawal. Patients, in whom
the rise of endogenous TSH by thyroxine withdrawal is connected
with a significant risk of complications, form a major group of can-
didates for rhTSH treatment. Serious health consequences, such
as major depression or heavy gastric symptoms, are imminent
after thyroxine withdrawal in some patients. What is clinically more
important, however, is that hypothyroidism induced by thyroxine
withdrawal may aggravate other serious diseases concomitant to
thyroid cancer or caused by DTC. Patients with circulatory or re-
nal insufficiency as well as patients with ischaemic brain disease
are most prone to hypothyroidism-induced consequences. This
category of indications for recombinant hTSH may be considered
as patient-related indications (Table 2).
The second category of contraindications to withdraw thyroid
hormones is cancer disease-related contraindications. During thy-
roxine withdrawal both hypothyroidism-related oedema and TSH
stimulation-related increase of tumour volume may induce or ag-
gravate the symptoms of compression in the surrounding normal
tissue (25, 3738). This is extremely dangerous in patients with brain
and skull or spine metastases, which may compress neural tissue
(3638). These patients constitute the most obvious candidates for
recombinant TSH-aided 131I treatment. Until now we have treated
five patients with spine metastases with the support of recombi-
nant hTSH (with six courses of therapy performed) (23, 24). No
pain increase due to compression of dorsal nerve roots was noted
during therapy or immediately after it in four of them (although in
one patient with spine metastasis an incident of distinct pain in-
Table 2. Indications for recombinant human TSH to support 131I therapy of differentiated thyroid carcinoma
Category of indication Cause Type of indication for rhTSH
Patient-related Hypopituitarism Lack of endogenous TSH
History of serious complications Contraindication for thyroxine withdrawal
during former thyroxine withdrawal
  severe forms of gastritis requiring hospitalisation
  major depression
  other symptoms of severe impairment
  of patients status or his quality of life
Concomitant diseases which may Contraindication for thyroxine withdrawal
be potentiated by thyroxine withdrawal
  circulatory insufficiency
  renal insufficiency
  ischaemic brain disease
  others
Cancer disease-related Metastases destroying pituitary gland Lack of endogenous TSH
Risk of compression on neural tissue Contraindication for thyroxine withdrawal
Brain and spinal cord metastases
Central skeleton (skull and spine) metastases
Risk of progression due to the prolonged Contraindication for thyroxine withdrawal
stimulation of TSH
Bone metastases
Brain and spinal cord metastases
Lymph node metastases
Lung metastases
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crease was observed during preceding 131I therapy after thyroxine
withdrawal). The posttherapeutic uptake of 131I was confirmed in 5
of 6 therapies. The short term response (regression or the stagna-
tion of the disease) was stated in three out of five patients.
Another very important indication for rhTSH results from the
fact that prolonged stimulation with TSH obtained during thyrox-
ine withdrawal may be dangerous for the induction of cancer
progression. This is a well-known clinical phenomenon, although
rarely determined in quantitative terms (26, 34). We saw it several
times, particularly in patients with bone metastases, when pain
started at hormone withdrawal due to the expansion of the tumour
volume but was not released after reintroduction of thyroxine, as
not only oedema but also increased proliferation were responsi-
ble for this effect. Also, lymph node metastases may grow very
quickly after thyroxine withdrawal (26).
It is widely accepted that thyroxine-induced TSH suppression
is a tool for reduction of DTC relapse. Mazzaferri et al. (1) showed
that even in the face of improper primary treatment of DTC (lack of
total surgery and/or lack of 131I therapy) thyroxine administration
reduced the recurrence rate and death rate from cancer in com-
parison to no treatment. Recent published reports indicate that a
prolonged lack of TSH suppression is a negative prognostic fac-
tor increasing the risk of recurrence of DTC (3941). In vitro stud-
ies with animal tissues show a distinct increase in the proliferation
rate of transformed follicular cells induced by recombinant hu-
man TSH (3, 42). Subacute TSH rise in DTC patients, lasting up to
46 weeks, which is connected with thyroxine withdrawal, may
also result in the induction of proliferation of cancer cells. The
increase of serum TSH after rhTSH administration is much short-
er, thus, it may have fewer negative consequences (9, 10, 21).
Further studies are needed to confirm this hypothesis.
The patients with a high risk of progression during thyroxine
withdrawal, who may benefit from rhTSH therapy, are patients with
large lymphonodal involvement (even after extensive surgery), with
T4 tumour, and patients with distant metastases. Brain metastas-
es form the strongest indication, followed by bone (particularly
skull and vertebral) metastases and mediastinal lymph node me-
tastases. The most often seen localisation of distant metastases
in DTC are lung metastases and they should also be included.
In fact, the first published case of the successful use of rhTSH
in the treatment of metastatic thyroid cancer was connected with
the reluctance to withdraw thyroxine replacement in a patient with
a very advanced disseminated cancer disease (25). Previous dis-
continuing of thyroxine for several weeks resulted in a quick growth
of local recurrence, which became visible, and possibly also bone
metastases. The stimulation of rhTSH enabled 131I treatment, which
was performed with a very high activity of 515 mCi of 131I and re-
sulted in a partial regression of the cancer disease and a distinct
improvement of the patients status and his quality of life. Multiple
metastases showed 131I uptake on posttherapeutic scintigrams,
which were not visible during the earlier diagnostics performed on
thyroxine withdrawal. However, the authors could not ultimately
define to what extent the obtained result was due to the high ac-
tivity of 131I applied. They assumed that the observed 131I trapping
was due only to rhTSH, but this may not ultimately be proved as
they did not perform a repeated diagnostic study with rhTSH at
that time. Nevertheless, the possibility that rhTSH reverted the
former lack of 131I trapping is very exciting.
In the disseminated differentiated thyroid carcinoma good re-
sults of therapy may be achieved only in these patients in whom
131I trapping ability is preserved and may be shown on a postther-
apeutic scintigram (8, 34). There are very few therapeutic possi-
bilities for DTC patients with metastases not concentrating 131I (34).
Only rarely may surgical excision be proposed. In most cases
chemotherapy is ineffective and radiotherapy may be applied only
as palliative treatment. Thyroxine suppressive therapy may be of
some worth in reducing the rate of progression but is unable to
effect regression of the disease (43). The important question is
whether rhTSH will be helpful in these patients. A report by Ru-
davsky and Freeman indicates such a possibility (25).
From the published reports on the effects of rhTSH aided ther-
apy in DTC we expect a description and evaluation of its efficacy
in three levels. First, whether the administration of recombinant
hTSH results in good 131I trapping by the tumour, confirmed on a
posthterapeutic 131I scintigram. It would be advantageous if this
effect could be compared to the results of thyroxine withdrawal,
but, in contrast to the diagnostic studies, in the case of radioiod-
ine treatment these studies may not be repeated immediately one
after the other. The results of previous 131I treatments and the pos-
sible dedifferentiation of tumour cells or disease progression have
always to be considered.
The second, more important aspect of the direct evaluation of
the results of 131I treatment is brought by a posttherapeutic dosim-
etry (28, 29). In most centres the results of 131I therapy have been
evaluated only qualitatively until now. However, some estimations
of the absorbed dose have been published (27, 28, 29) and they
are now being more widely applied to bring information on the
gain obtained by rhTSH. A very elegant study has been published
recently by Rotman-Pikielny et al. (27), who estimated the dose
absorbed by 131I concentrating liver metastases treated with the
aid of rhTSH. In this study, already mentioned above, the prether-
apeutic dosimetry approach resulted in a choice of a minimal ef-
fective activity of 131I needed to provide the tumoricidal dose of 80
Gy, as estimated by Maxon (28, 29). The 131I activity given was low
(65 mCi) in comparison to the normally used fixed activities. What
is very impressive is that it resulted in a distinct regression of the
total volume of multiple liver metastases of malignant struma ova-
rii. This approach may be applied in other studies in order to draw
final conclusions on the efficacy of rhTSH in the 131I therapy of
DTC.
The third and most important level of the evaluation of the
rhTSH significance for 131I therapy of DTC will be the final estima-
tion of remission rate and survival in the treated patients. This may
not be expected in the next few years, as we know that long times
of observations are needed in DTC to appraise any new treatment
modality (34). An additional obstacle is connected with the fact
that recombinant TSH is introduced often in patients who have
already received some courses of therapy after thyroxine with-
drawal and the impact of both types of therapies may not be sep-
arated.
Potential advantages of the therapeutic use of rhTSH should
not conceal the possible adverse effects. The results of diagnos-
tic studies were rather reassuring, but they may not automatically
be widened on therapeutic application. In this context we should
indicate the recent report of Vargas et al. (26), who described a
hemiplegia complicating the course of rhTSH-aided 131I therapy in
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a hypothyroid patient with DTC metastatic to the brain. This pa-
tient suffered from secondary hypothyroidism due to a metastatic
clival lesion that involved the pituitary gland. 48 h after rhTSH ad-
ministration, still before radioiodine therapy, they observed a haem-
orrhage in another brain metastasis causing right-side hemiple-
gia, which resolved only partially later on. The authors considered
a direct effect of rhTSH on tumour growth and on vascular perme-
ability in a previously quiescent metastasis in combination with
hypothyroidism-induced coagulopathy. The obtained level of se-
rum TSH was very high (up to more than 500 mU/l), thus a de-
crease in the metabolism of the recombinant protein was taken
into consideration as well. The possibility of up-regulation of TSH
receptors was also speculated. The authors cautioned the use of
rhTSH in patients with brain metastases who are hypothyroid. In
this context we should also mention a case of pathologic verte-
bral fracturing. Its symptoms started some 12 hours after 131I ad-
ministration (100 mCi) to an rhTSH pretreated patient (23). The
incident caused paraplegia. Simultaneously, the loss of 131I up-
take in the metastatic vertebra was observed. Thus, we assume
that it was not caused by 131I therapy per se. However, an inde-
pendent event, not causatively related to rhTSH administration,
may not be excluded.
In conclusion, the final results of recombinant human TSH
application for 131I therapy of differentiated thyroid carcinoma are
probably a matter of time, but at present we should evaluate the
efficacy of rhTSH from a shorter perspective. When we compare
the stimulation with endogenous TSH obtained by thyroxine with-
drawal to the administration of recombinant TSH during thyroxine
therapy, we should stress the comparable results of 131I- and thy-
roglobulin-based follow up, the presence of euthyroid status dur-
ing the follow-up examinations and radioiodine therapy, and final-
ly the short duration of TSH rise which obviously decreases the
risk of complications and may decrease the risk of cancer pro-
gression  although particularly this last effect requires more clin-
ical evidence.
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